Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
Autologous stem cell transplantation (ASCT) is indicated in a number of hematologic malignancies, including multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Relapse, however, remains 1 of the main causes of post-ASCT failure, and several strategies are being investigated to decrease the risk of relapse of progression. Recent advances in the treatment of hematological malignancies have included adoptive transfer of genetically modified T cells that express chimeric antigen receptors or T cell receptors, as well the use of checkpoint inhibitors. Early clinical results in nontransplantation patients have been very promising. This review will focus on the use of gene-modified T cells and checkpoint inhibitors in stem cell transplantation.
Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York. Electronic address: peralesm@mskcc.org.
Miguel-Angel
MA
Perales
Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.
Craig S
CS
Sauter
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Philippe
P
Armand
D019264:Adoptive Transfer; D000818:Animals; D064592:Autografts; D019337:Hematologic Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation
D011948:Receptors, Antigen, T-Cell
Adoptive cell therapy; Autologous stem cell transplantation; Checkpoint inhibitors; Immunotherapy; Lymphoma; Myeloma